Esperance Pharmaceuticals has started Phase 1 clinical studies of a drug designed to seek and destroy cancer cells. The Baton Rouge-based biotech firm is testing EP-100 in patients with advanced solid tumors. Preclinical studies have shown the drug selectively kills cancer cells without hurting healthy tissue, says Hector Alila, Esperance president and founder. The trial targets patients with breast, ovarian, endometrial, pancreatic or prostate cancer; preclinical studies show the drug reduced established tumors in mice.
B.R. biotech firm starts clinical studies on cancer drug
Sign up for the free Daily Report email – local news about the people, companies and issues that impact business impact business in Baton Rouge and beyond.
